1例COVID-19危重型患者免疫治疗的疗效评估

目的探索COVID-19危重型患者免疫支持治疗的理论依据,以期为后续COVID-19危重型患者免疫相关治疗提供部分病例支持。方法以我院收治的1例COVID-19危重型患者为对象,关注其免疫相关指标包括T淋巴细胞数量、CD4+T和CD8+T细胞计数的变化情况结合患者炎症指标白介素-6(IL-6)及临床症状的变化情况,进行相关性分析,评估免疫支持治疗的疗效及对患者预后的影响。结果患者药物治疗过程与临床症状的变化情况有相关性,炎症指标IL-6、T淋巴细胞数量的变化情况与药物治疗方案的调整变化一致,提示免疫治疗有效。结论增加T淋巴细胞数量的免疫支持治疗可能是COVID-19危重型患者的有效治疗方法之一。

Retrospective Analysis and Evaluation of the Efficacy of Immunotherapy in A Case of Severe Patient with COVID-19

OBJECTIVE To explore the theoretical basis of immune support therapy for critical patients with COVID-19,and to provide partial case support for subsequent immunological treatment for critical patients with COVID-19. METHODS A case of severe patient with COVID-19 was admitted to our hospital as a subject. The changes of immune-related indicators including the number of T lymphocytes,CD4+T and CD8+ T cell counts combined with the patient’ s inflammation index interleukin-6( IL-6) and the change of clinical symptoms we paid attention.The correlation analysis was conducted to evaluate the efficacy of immune support therapy and its impact on the prognosis of patients. RESULTS The patient’ s drug treatment process was correlated with the changes in clinical symptoms.The changes in the inflammatory markers IL-6 and T lymphocytes were consistent with the adjustment changes in the drug treatment plan,which suggested that immunotherapy was effective. CONCLUSION Increasing the number of T lymphocytes in immunosupportive therapy may be one of the effective treatment methods for critical patients with COVID-19.